Abstract 1256P
Background
Lung cancer is a cancer type with high morbidity and mortality in the word, the clinical prognosis of lung cancer patients is still poor, the main reason is the lack of effective early screening and diagnosis methods. Plasma circRNAs detected by droplet digital PCR may be ideal markers for liquid biopsy. However, droplet digital PCR detection of circRNAs in plasma for (early) diagnosis of lung adenocarcinoma has been rarely reported.
Methods
RNA sequencing analysis was performed in plasma from patients with early lung adenocarcinoma and healthy individuals. Droplet digital PCR was used to verify the differentially expressed genes. We evaluated their diagnostic efficacy and predict their biological functions of target genes.
Results
The copy numbers of circLZIC and circCEP350 in the plasma of lung adenocarcinoma patients were significantly higher than in plasma of healthy people (P<0.01), they are closely related to tumor size (P<0.05) and TNM stage (P<0.05),and the copy numbers in postoperative plasma of the same patient were significantly lower than those in preoperative plasma (P<0.05).ROC curve analysis showed that circLZIC (AUC=0.782) and circCEP350 (AUC=0.764) alone and in combination (AUC=0.863) had diagnostic value in lung adenocarcinoma, circLZIC (AUC=0.786) and circCEP350 (AUC=0.546) alone and in combination (AUC=0.803) had diagnostic value in early lung adenocarcinoma.Bioinformatics analysis revealed that circLZIC and circCEP350 had more binding sites with multiple microRNAs. Their target genes were enriched in several signaling pathways.
Conclusions
The copy numbers of circLZIC and circCEP350 were higher in plasma of lung adenocarcinoma patients than in plasma of healthy controls, significantly correlated with tumor size and TNM stage, and closely related to the occurrence and development of tumors. These circRNAs may serve as molecular markers for the diagnosis of lung adenocarcinoma.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1785P - Changes in bone mineral density, trabecular bone score and body composition in metastatic hormone-sensitive prostate cancer (mHSPC) patients randomized to receive androgen deprivation + enzalutamide plus/minus zoledronic acid: The BonEnza study
Presenter: Alberto Dalla Volta
Session: Poster session 14
1787P - Prostate specific membrane antigen positron emission tomography (PSMA PET)-directed clinical outcomes in metastatic hormone-sensitive prostate cancer (mHSPC): Implications for the STAMPEDE2 trial design
Presenter: Hoda Abdel-Aty
Session: Poster session 14
1789P - Low- and high-volume disease in mHSPC: From CHAARTED to PSMA PET
Presenter: Lena Unterrainer
Session: Poster session 14
1790P - Utilisation rates of treatment intensification for metastatic hormone sensitive prostate cancer (mHSPC) in England, UK
Presenter: Joanna Dodkins
Session: Poster session 14
1791P - Molecular profiling and prognostic relevance of low PTEN expression in metastatic hormone-sensitive prostate cancer patients
Presenter: Marta Garcia De Herreros
Session: Poster session 14
1792P - Effects of enzalutamide on overall survival +/- early docetaxel in participants aged less than 70 yrs versus greater than or equal to 70 yrs in ENZAMET (ANZUP 1304)
Presenter: Lisa Horvath
Session: Poster session 14
1793P - PPROSTRATEGY: A SOGUG randomized trial of androgen deprivation therapy (ADT) plus docetaxel (dct) +/- nivolumab (nivo) or ipilimumab-nivolumab (ipi-nivo) in high-volume metastatic hormone-sensitive prostate cancer (hvHSPCa) - Safety and toxicity profiles from the pilot phase
Presenter: Jose Arranz Arija
Session: Poster session 14